Morgan Stanley Call 129 6MK 20.06.../ DE000ME2EZG1 /
2024-08-30 6:23:52 PM | Chg.-0.020 | Bid10:00:35 PM | Ask10:00:35 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.480EUR | -4.00% | - Bid Size: - |
- Ask Size: - |
MERCK CO. D... | 129.00 - | 2025-06-20 | Call |
GlobeNewswire
07-17
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
07-09
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination ...
GlobeNewswire
06-25
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
06-03
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
05-29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-06
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...